Madrigal Pharmaceuticals, Inc. Common Stock
MDGL
$493.11
-9.83%
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Its lead product, Rezdiffra (resmetirom), is a first-in-class, once-daily oral thyroid hormone receptor beta agonist targeting key underlying causes of MASH, positioning the company as a pioneer in this emerging therapeutic category. The current investor narrative centers on the commercial launch trajectory of Rezdiffra, with revenue rapidly scaling from $14.6 million in Q2 2024 to $311.3 million in Q1 2026, though the company remains unprofitable as it invests heavily in sales and marketing. Debate surrounds the pace of market adoption, competitive dynamics, and the path to sustained profitability, with recent analyst actions remaining largely bullish.…
MDGL
Madrigal Pharmaceuticals, Inc. Common Stock
$493.11
Related headlines
MDGL 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Madrigal Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $681.80 and implied upside of +38.3% versus the current price.
Average Target
$681.80
0 analysts
Implied Upside
+38.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$553 - $964
Analyst target range
Madrigal is covered by 14 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.44 on a 1-5 scale). The average price target is $679.64, implying approximately 24.8% upside from the current price of $544.51. The distribution shows a bullish lean, with no sell ratings and only one neutral rating (B of A Securities). The consensus reflects confidence in Rezdiffra's commercial potential and the company's leadership in the MASH space. The target range spans from a low of $553.00 to a high of $964.00, representing a wide spread of 74.3% from low to high, indicating significant uncertainty about the pace of adoption and ultimate market size. The high target of $964 assumes rapid market penetration, potential label expansion, and strong pricing power, while the low target of $553 suggests a more conservative outlook with slower uptake or competitive pressure. Recent analyst actions have been predominantly reaffirmations of Buy ratings, with no downgrades, signaling sustained optimism. The wide target spread highlights the binary nature of the stock, where outcomes depend heavily on commercial execution and pipeline developments. Investors should monitor quarterly revenue trends and any updates on clinical trials for catalysts that could narrow this range.
Bulls vs Bears: MDGL Investment Factors
Madrigal presents a compelling growth story as the first approved therapy for MASH, with revenue scaling rapidly and a consensus Strong Buy rating. However, the company remains unprofitable with negative free cash flow, and the sequential revenue dip in Q1 2026 warrants caution. The bull case hinges on sustained revenue acceleration and margin expansion, while the bear case centers on cash burn and competitive entry. The single most important tension is whether Rezdiffra's adoption can maintain its trajectory to justify the current valuation, as any slowdown could trigger multiple compression. Currently, the evidence slightly favors the bull case given the massive market opportunity and improving operating leverage, but investors must monitor quarterly trends closely.
Bullish
- First-in-Class MASH Drug with Rapid Revenue Growth: Rezdiffra revenue grew from $14.6M in Q2 2024 to $311.3M in Q1 2026, a 126.8% YoY increase, demonstrating strong commercial uptake in a large unmet market.
- High Gross Margin and Improving Operating Leverage: Gross margin is 94.1% (TTM), typical for biotech products, and operating margin improved from -1110% in Q2 2024 to -29.8% in Q1 2026 as revenue scales faster than expenses.
- Strong Analyst Consensus and Significant Upside: 14 analysts rate it Strong Buy with an average target of $679.64, implying 24.8% upside from $544.51. The high target of $964 suggests potential 77% upside.
- Massive Total Addressable Market Opportunity: MASH affects millions globally with no approved therapies until Rezdiffra, positioning Madrigal to capture a multi-billion dollar market as the first mover.
Bearish
- Unprofitable with Negative Free Cash Flow: Net loss of $94.4M in Q1 2026 and TTM free cash flow of -$272.4M indicate the company is still burning cash heavily, requiring either revenue acceleration or capital raises.
- Sequential Revenue Dip Raises Concerns: Revenue declined from $321.1M in Q4 2025 to $311.3M in Q1 2026, a 3% sequential drop, which could signal slowing adoption or seasonal effects that need monitoring.
- High Valuation Premium on Trailing Basis: Trailing P/S of 13.6x is 70-127% above the biotech industry average of 6-8x, leaving little room for execution missteps or competitive threats.
- Binary Risk from Clinical and Regulatory Dependence: The stock's negative beta (-1.056) and 52-week range ($286-$615) reflect high idiosyncratic risk tied to Rezdiffra's commercial success and potential pipeline setbacks.
MDGL Technical Analysis
Madrigal's stock is in a strong long-term uptrend, with a 1-year price change of +82.0%, significantly outperforming the S&P 500's +16.5% gain. The current price of $544.51 sits at 74.5% of its 52-week range ($286.44 to $615.00), indicating the stock is in the upper half of its range but not yet at overbought extremes. This positioning suggests sustained bullish momentum with room to run, though the stock is closer to resistance than support. Over the past 1-month and 3-month periods, the stock has gained 6.8% and 6.3%, respectively, showing accelerating short-term momentum that aligns with the longer-term uptrend. The 1-month relative strength versus the S&P 500 is +6.0%, confirming the stock is outperforming the market. However, the 1-year relative strength of +65.5% highlights the magnitude of the longer-term outperformance, suggesting the stock may be due for a consolidation period. The 52-week high of $615.00 represents key resistance, while the 52-week low of $286.44 serves as major support. A breakout above $615 could signal a resumption of the uptrend and target new highs, while a breakdown below $286 would be a bearish reversal. The stock's beta of -1.056 is unusual, indicating an inverse relationship with the market, which may reflect its idiosyncratic, binary nature tied to clinical and regulatory milestones. This negative beta implies the stock can rally during market downturns, offering a hedge, but also means it can fall when the market rises, adding complexity to risk management.
Beta
-1.06
-1.06x market volatility
Max Drawdown
-29.4%
Largest decline past year
52-Week Range
$290-$615
Price range past year
Annual Return
+70.1%
Cumulative gain past year
| Period | MDGL Return | S&P 500 |
|---|---|---|
| 1m | -8.2% | -0.7% |
| 3m | -4.0% | +2.9% |
| 6m | +0.8% | +7.2% |
| 1y | +70.1% | +16.9% |
| ytd | -17.0% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDGL Fundamental Analysis
Madrigal's revenue has grown exponentially since the launch of Rezdiffra, from $14.6 million in Q2 2024 to $311.3 million in Q1 2026, representing a YoY growth rate of 126.8% in the most recent quarter. The sequential growth from Q4 2025 ($321.1 million) to Q1 2026 ($311.3 million) shows a slight dip, but the overall trajectory is sharply upward, driven by the commercial launch of its first-in-class MASH therapy. The company is still in the early stages of market penetration, and the revenue ramp reflects strong initial demand, though sustainability will depend on reimbursement, physician adoption, and competitive entry. The company remains unprofitable, with a net loss of $94.4 million in Q1 2026, though this loss has narrowed from $152.0 million in Q2 2024. Gross margin is exceptionally high at 94.1% (TTM), typical for biotech products with low cost of goods sold, but operating margin is deeply negative at -31.3% due to heavy R&D and SG&A spending. The net margin of -30.1% reflects the investment phase, but the trend is improving as revenue scales faster than expenses. Madrigal has a debt-to-equity ratio of 0.59, indicating moderate leverage, and a current ratio of 4.01, suggesting ample liquidity. However, free cash flow is negative at -$272.4 million (TTM), and the company has been funding operations through cash reserves and financing activities. The ROE of -47.8% is deeply negative due to losses, but this is expected for a commercial-stage biotech. The company's cash position of $232.2 million (Q1 2026) provides a runway, but continued cash burn necessitates either accelerating revenue growth or additional capital raises to achieve self-sustainability.
Quarterly Revenue
$311337000.0B
2026-03
Revenue YoY Growth
+126.8%
YoY Comparison
Gross Margin
91.4%
Latest Quarter
Free Cash Flow
$-272413000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDGL Overvalued?
Since Madrigal has negative net income (TTM net loss of -$94.4 million), the P/E ratio is not meaningful, so we lead with the price-to-sales (P/S) ratio. The trailing P/S ratio is 13.6x, while the forward P/S (based on estimated revenue of $5.05 billion) is approximately 2.6x, implying the market expects massive revenue growth. The wide gap between trailing and forward multiples reflects the market's pricing of a steep growth trajectory. Compared to the biotechnology industry average P/S of roughly 6-8x, Madrigal's trailing P/S of 13.6x represents a premium of 70-127%, which is justified by its first-mover advantage in the large MASH market and rapid revenue growth. However, the forward P/S of 2.6x suggests the stock is actually cheap relative to expected future sales, indicating the market is pricing in aggressive growth but not yet fully reflecting it. Historically, Madrigal's P/S ratio has ranged from near zero (pre-revenue) to over 400x in early 2024. The current trailing P/S of 13.6x is near the lower end of its historical range since generating revenue, suggesting the stock is not overvalued relative to its own history. The PB ratio of 21.7x is elevated but reflects the intangible value of its approved product and pipeline. Overall, the valuation appears reasonable given the growth prospects, but it hinges on the company's ability to sustain revenue growth and achieve profitability.
PE
-45.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-50.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Madrigal's primary financial risk is its continued unprofitability and negative free cash flow of -$272.4M (TTM), which necessitates either rapid revenue growth or external financing. The net loss of $94.4M in Q1 2026, though narrowing, still represents a significant cash burn rate. With a cash balance of $232.2M, the company has limited runway without additional capital raises, which could dilute shareholders. The debt-to-equity ratio of 0.59 is moderate, but the negative ROE of -47.8% highlights the drag from losses. Revenue concentration in a single product (Rezdiffra) amplifies operational risk if adoption slows or competition emerges.
Market & Competitive Risks: The stock trades at a trailing P/S of 13.6x, a premium to the biotech industry average of 6-8x, making it vulnerable to valuation compression if growth disappoints. Its negative beta of -1.056 indicates an inverse correlation with the market, which can lead to sharp moves during market rallies. Competitive threats include potential entrants from larger pharma companies targeting MASH, which could erode Rezdiffra's first-mover advantage. Regulatory risks include label restrictions or safety concerns that could limit the addressable market. The wide analyst target range ($553-$964) reflects high uncertainty about commercial execution.
Worst-Case Scenario: In a severe adverse scenario, Rezdiffra's adoption could stall due to safety issues, competitive launch, or payer pushback, leading to revenue deceleration and widening losses. The stock could retest its 52-week low of $286.44, representing a potential 47% decline from the current price of $544.51. Historical max drawdown of -29.36% provides a reference, but given the binary nature, a drop to $286 would imply a loss of approximately $258 per share. This scenario would likely involve analyst downgrades and a loss of investor confidence in the commercial viability of Rezdiffra.